AFT Pharmaceuticals continues to expand its global footprint.
Cheaper, unregulated cannabis products are undermining the local industry, which will struggle to compete on price.
The US-developed test has been scientifically validated in NZ, but has yet to be assessed by the Ministry of Health.
This is the second investment Te Pūia Tāpapa has made with the New Zealand Superannuation Fund.